Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Rule 8.3- Torex Retail PLC

28 Jul 2005 12:43

Artemis Investment Management28 July 2005 Date of Disclosure 28 JULY 2005 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS Date of dealing 27 JULY 2005 Dealing in TOREX RETAIL (name of company) 1) Class of securities (eg ordinary shares) ORDINARY GBP0.05 2) Amount bought Amount sold Price per unit 605,000 IN-SPECIE 3) Resultant total of the same class owned or controlled (and percentage of class) 12,880,000 (6.6944%) 4) Party making disclosure ARTEMIS INVESTMENT MANAGEMENT LTD 5) EITHER (a) Name of purchaser/vendor (Note 1) OR (b) if dealing for discretionary client(s), name of fund management organisation ARTEMIS INVESTMENT MANAGEMENT LTD 6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) NO (ii) offeree company NO Specify which category or categories of associate (1-8 overleaf) If category (8), explain (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) YES Signed, for and on behalf of the party named in (4) above N/A (Also print name of signatory) MARK SCOTT Telephone and extension number 0131 718 0430 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or which an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8 Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. Note 7. The resultant total percentage holding of the class of relevant security is to be calculated by reference to the percentage held and in issue outside treasury. For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Takeovers and Mergers, Monitoring Section, Tel. No:020 7638 0129. Email: monitoring@disclosure.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jan 20267:00 amRNSSecondary Trading Following Cancellation
7th Jan 20267:00 amRNSCancellation - Tissue Regenix Group Plc
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
22nd Dec 20254:08 pmRNSResult of General Meeting and Cancellation
17th Dec 20256:00 pmRNSTissue Regenix Group
8th Dec 20257:00 amRNSUpdate re. proposed cancellation of shares
4th Dec 20252:40 pmRNSProposed £17.5m CLN raise, cancellation of Trading
1st Dec 20257:00 amRNSFurther re. financial update and funding plans
7th Nov 20257:00 amRNSFinancial update and funding plans
22nd Oct 20253:29 pmRNSStatement re. Suspension
22nd Oct 20252:02 pmRNSSuspension - Tissue Regenix Group PLC
17th Oct 20257:00 amRNSCFO joins Board
16th Oct 20257:00 amRNSUpdate re. FY24 & H125 restatement & Board Changes
9th Oct 20257:00 amRNSHolding(s) in Company
6th Oct 20253:29 pmRNSHolding(s) in Company
3rd Oct 20253:01 pmRNSHolding(s) in Company
2nd Oct 20254:43 pmRNSHolding(s) in Company
1st Oct 20255:35 pmRNSHolding(s) in Company
30th Sep 20257:00 amRNSHalf-year Report
17th Sep 20257:00 amRNSNotice of Results
8th Sep 20257:01 amRNSHalf-Year Trading Update and Notice of Results
8th Sep 20257:00 amRNSBoard Changes
1st Aug 20257:00 amRNSDirectorate Change
23rd Jul 20251:52 pmRNSResult of AGM
4th Jul 20257:00 amRNSGrant of share options
27th Jun 20257:00 amRNSPosting of Annual Report & Notice of AGM
25th Jun 20257:00 amRNSFinal results for the year ended 31 December 2024
9th Jun 20257:00 amRNSCE & UKCA certification for OrthoPure® XT
24th Apr 20259:38 amRNSForm 8.5 (EPT/NON-RI)- Tissue Regenix Group Plc
15th Apr 20259:23 amRNSForm 8.5 (EPT/NON-RI)
10th Apr 20259:09 amRNSForm 8.5 (EPT/NON-RI)
9th Apr 202510:45 amRNSForm 8.5 (EPT/NON-RI)
8th Apr 20257:00 amRNSConclusion of Strategic Review & Offer Period
7th Apr 20258:46 amRNSForm 8.5 (EPT/NON-RI)
1st Apr 20259:12 amRNSForm 8.5 (EPT/NON-RI)
31st Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
27th Mar 20257:00 amRNSEuropean patent granted
25th Mar 20258:58 amRNSForm 8.5- Tissue Regenix Group Plc
21st Mar 20258:36 amRNSForm 8.5 (EPT/NON-RI)
20th Mar 20259:19 amRNSForm 8.5 (EPT/NON-RI)
19th Mar 20258:55 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
18th Mar 20257:00 amRNSCompany update
12th Mar 20259:27 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 20259:30 amRNSForm 8.5 (EPT/NON-RI)
6th Mar 20259:29 amRNSForm 8.5 (EPT/NON-RI)
5th Mar 20258:54 amRNSForm 8.5 (EPT/NON-RI)
4th Mar 20259:28 amRNSForm 8.5 (EPT/NON-RI)
3rd Mar 20259:21 amRNSForm 8.5 (EPT/NON-RI)
21st Feb 20258:56 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.